- Report
- March 2025
- 175 Pages
Global
From €4089EUR$4,490USD£3,516GBP
- Report
- May 2024
- 134 Pages
Global
From €5918EUR$6,499USD£5,090GBP
- Report
- May 2024
- 133 Pages
Global
From €5918EUR$6,499USD£5,090GBP
- Report
- March 2025
- 185 Pages
Global
From €4098EUR$4,500USD£3,524GBP
- Report
- August 2022
- 115 Pages
Global
From €4098EUR$4,500USD£3,524GBP
- Drug Pipelines
- April 2024
- 180 Pages
Global
From €2732EUR$3,000USD£2,349GBP
- Report
- April 2023
- 90 Pages
Middle East, Africa
From €4326EUR$4,750USD£3,720GBP
- Report
- March 2019
- 20 Pages
Global
€9107EUR$10,000USD£7,832GBP
- Report
- August 2023
- 112 Pages
Global
From €3500EUR$4,117USD£3,115GBP
- Report
- April 2025
- 50 Pages
Global
From €2413EUR$2,650USD£2,075GBP
Axitinib is a type of drug used to treat kidney cancer. It is a tyrosine kinase inhibitor, meaning it works by blocking certain proteins that help cancer cells grow and divide. Axitinib is used to treat advanced renal cell carcinoma, a type of kidney cancer. It is usually given after other treatments, such as surgery, have failed. Axitinib is usually taken orally, once a day. Common side effects include fatigue, diarrhea, nausea, and high blood pressure.
Axitinib is one of several drugs used to treat kidney cancer. Other drugs used to treat kidney cancer include sunitinib, pazopanib, and cabozantinib. Each of these drugs works differently and has different side effects.
Axitinib is marketed by Pfizer, Inc. Other companies that market drugs for kidney cancer include Novartis, Bristol-Myers Squibb, and Merck & Co. Show Less Read more
